Otonomy Appoints Jill Broadfoot to Board of Directors
August 19 2021 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced the appointment of Jill Broadfoot to
its board of directors.
“Jill is an excellent addition to the board with strong
strategic, operational and financial expertise within the
biopharmaceutical sector,” said David A. Weber, Ph.D., president
and CEO of Otonomy. “We are excited to welcome her as we continue
our growth trajectory and make progress to achieving our clinical
milestones.”
Since 2018, Ms. Broadfoot has served as chief financial officer
(CFO) of aTyr Pharma, Inc., a biotherapeutics company. Prior to
joining aTyr, Ms. Broadfoot served as CFO of Emerald Health
Pharmaceuticals Inc. and Emerald Health Bioceuticals Inc. where she
was responsible for establishing operations for the U.S.-based
pharmaceutical and bioceuticals entities. Previously, she served as
Vice President, U.S. Corporate Controller at GW Pharmaceuticals,
CFO of Vical Inc. and held various financial positions at DJO
Global. Ms. Broadfoot also served as an audit manager at Ernst
& Young LLP. She holds a B.S. in business administration and
accounting from San Diego State University and is a Certified
Public Accountant.
“I am pleased to join the Otonomy board of directors as the
company continues to build on its strong neurotology foundation and
advances its clinical and preclinical pipeline,” said Jill
Broadfoot. “I look forward to working with the board and to
contributing to the company’s continued progress and success.”
About OtonomyOtonomy is a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology. The company pioneered the application of drug delivery
technology to the ear in order to develop products that achieve
sustained drug exposure from a single local administration. This
approach is covered by a broad patent estate and is being utilized
to develop a pipeline of products addressing important unmet
medical needs with a focus on hearing loss and tinnitus. For
additional information please visit www.otonomy.com.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or the future financial or operating performance of Otonomy.
Forward-looking statements in this press release include, but are
not limited to, statements related to Otonomy’s development plans
and timelines for its product candidates and programs; the
potential benefits and advantages of Otonomy’s product candidates
and programs; expectations regarding preclinical programs,
including the potential benefits and development activities;
expectations regarding Otonomy’s ability to advance its pipeline;
and statements by Otonomy’s president and CEO and a member of the
Board. Otonomy’s expectations regarding these matters may not
materialize, and actual results in future periods are subject to
risks and uncertainties. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
these risks and uncertainties, including but not limited to:
Otonomy’s ability to accurately forecast financial results;
Otonomy’s expectation that it will incur significant losses for the
foreseeable future; Otonomy’s ability to obtain additional
financing; Otonomy’s dependence on the regulatory success and
advancement of its product candidates; competition in the
biopharmaceutical industry; Otonomy’s dependence on third parties
to conduct nonclinical studies and clinical trials, and for the
manufacture of its product candidates; Otonomy’s ability to protect
its intellectual property in the United States and throughout the
world and to ensure compliance with various laws and regulations in
countries in which it conducts clinical trials; expectations
regarding potential therapy benefits, market size, opportunity and
growth; Otonomy’s ability to manage operating expenses;
implementation of Otonomy’s business model and strategic plans for
its business, products and technology; general economic and market
conditions; and other risks. Information regarding the
foregoing and additional risks may be found in the section entitled
"Risk Factors" in Otonomy’s Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission (SEC) on August 4,
2021, and Otonomy’s future reports to be filed with the SEC. The
forward-looking statements in this press release are based on
information available to Otonomy as of the date hereof. Otonomy
disclaims any obligation to update any forward-looking statements,
except as required by law.
Contacts:
Media InquiriesSpectrum ScienceChloé-Anne RamseyVice
President404.865.3601cramsey@spectrumscience.com
Investor InquiriesWestwicke ICRRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Oct 2023 to Oct 2024